JP2017538669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538669A5 JP2017538669A5 JP2017520986A JP2017520986A JP2017538669A5 JP 2017538669 A5 JP2017538669 A5 JP 2017538669A5 JP 2017520986 A JP2017520986 A JP 2017520986A JP 2017520986 A JP2017520986 A JP 2017520986A JP 2017538669 A5 JP2017538669 A5 JP 2017538669A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- group
- mdsc
- human genetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021102148A JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14190370.8A EP3012271A1 (en) | 2014-10-24 | 2014-10-24 | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| EP14190370.8 | 2014-10-24 | ||
| PCT/IB2015/058124 WO2016063233A1 (en) | 2014-10-24 | 2015-10-21 | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102148A Division JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538669A JP2017538669A (ja) | 2017-12-28 |
| JP2017538669A5 true JP2017538669A5 (2) | 2018-11-29 |
| JP6918279B2 JP6918279B2 (ja) | 2021-08-11 |
Family
ID=51868772
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520986A Active JP6918279B2 (ja) | 2014-10-24 | 2015-10-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2021102148A Active JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A Pending JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102148A Active JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A Pending JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170247464A1 (2) |
| EP (4) | EP3012271A1 (2) |
| JP (3) | JP6918279B2 (2) |
| CA (1) | CA2964203C (2) |
| DK (2) | DK3209691T3 (2) |
| ES (2) | ES3060595T3 (2) |
| HU (1) | HUE050318T2 (2) |
| PL (2) | PL3209691T3 (2) |
| WO (1) | WO2016063233A1 (2) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| AU2016310348B2 (en) | 2015-08-26 | 2023-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist |
| WO2017068164A1 (en) * | 2015-10-21 | 2017-04-27 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| IL262251B2 (en) | 2016-04-14 | 2023-09-01 | Ose Immunotherapeutics | New anti-syrap antibodies and their medical applications |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| WO2018008470A1 (ja) * | 2016-07-05 | 2018-01-11 | 国立大学法人神戸大学 | 抗腫瘍剤 |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| AU2017371070B2 (en) | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| CN110536693B (zh) | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| AU2018210235A1 (en) * | 2017-01-18 | 2019-08-15 | Nant Holdings Ip, Llc | Modulation of tumor cell susceptibility |
| KR20190129046A (ko) * | 2017-02-15 | 2019-11-19 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Nk 세포를 활성화시키기 위한 조성물 및 방법 |
| JP7262440B2 (ja) | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｃｄ４７抗体及びその使用 |
| EP3694881A1 (en) | 2017-10-13 | 2020-08-19 | OSE Immunotherapeutics | Modified anti-sirpa antibodies and uses thereof |
| JP2021517130A (ja) | 2018-03-13 | 2021-07-15 | オーセ イミュノセラピューティクスＯｓｅ Ｉｍｍｕｎｏｔｈｅｒａｐｅｕｔｉｃｓ | 抗ヒトＳＩＲＰａｖ１抗体の使用および抗ｖ１抗体を製造する方法 |
| PE20201265A1 (es) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| JP7337099B2 (ja) | 2018-05-25 | 2023-09-01 | アレクトル エルエルシー | 抗ｓｉｒｐａ抗体およびその使用法 |
| WO2019240218A1 (ja) | 2018-06-14 | 2019-12-19 | 株式会社明治 | 免疫チェックポイント阻害療法を促進するための組成物 |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| EP3820887A4 (en) | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| BR112021005585A2 (pt) | 2018-09-27 | 2021-06-29 | Celgene Corporation | proteínas de ligação a sirpa e métodos de uso das mesmas |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| BR112021007286A2 (pt) | 2018-10-19 | 2021-07-27 | Ohio State Innovation Foundation | células furtivas terapêuticas nanoprojetadas |
| CN114126648A (zh) | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| US20200400662A1 (en) | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| KR20230018475A (ko) | 2020-06-01 | 2023-02-07 | 알렉소 온콜로지 인크. | 암 치료용 저메틸화제를 포함하는 병용 요법 |
| CN111808800B (zh) * | 2020-07-20 | 2022-08-26 | 中南大学湘雅二医院 | 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| CN116472351A (zh) | 2021-08-17 | 2023-07-21 | 杭州九源基因工程有限公司 | 靶向SIRPα的单克隆抗体及其用途 |
| US20240010701A1 (en) | 2022-06-01 | 2024-01-11 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| EP4619435A1 (en) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
| CN115896015B (zh) * | 2023-02-08 | 2023-09-29 | 上海诚益生物科技有限公司 | 一种髓系来源抑制性细胞的体外培养方法 |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1048299A1 (en) | 1999-04-28 | 2000-11-02 | Faculteit der Geneeskunde van de Vrije Universiteit | Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| JP2011500569A (ja) * | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| ES2582340T3 (es) * | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| HRP20150553T1 (hr) | 2009-05-15 | 2015-08-28 | University Health Network | Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju |
| GB201015765D0 (en) * | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| WO2012149416A2 (en) * | 2011-04-28 | 2012-11-01 | University Of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013056352A1 (en) * | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| NZ710695A (en) * | 2013-02-06 | 2020-05-29 | Inhibrx Inc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| CN106456749B (zh) | 2014-03-11 | 2021-03-30 | 小利兰·斯坦福大学托管委员会 | 抗SIRPα抗体和双特异性巨噬细胞增强型抗体 |
-
2014
- 2014-10-24 EP EP14190370.8A patent/EP3012271A1/en not_active Withdrawn
-
2015
- 2015-10-21 EP EP25219878.3A patent/EP4691569A3/en active Pending
- 2015-10-21 WO PCT/IB2015/058124 patent/WO2016063233A1/en not_active Ceased
- 2015-10-21 CA CA2964203A patent/CA2964203C/en active Active
- 2015-10-21 ES ES20177260T patent/ES3060595T3/es active Active
- 2015-10-21 JP JP2017520986A patent/JP6918279B2/ja active Active
- 2015-10-21 DK DK15794641.9T patent/DK3209691T3/da active
- 2015-10-21 PL PL15794641T patent/PL3209691T3/pl unknown
- 2015-10-21 EP EP15794641.9A patent/EP3209691B1/en not_active Revoked
- 2015-10-21 US US15/518,803 patent/US20170247464A1/en not_active Abandoned
- 2015-10-21 PL PL20177260.5T patent/PL3783027T3/pl unknown
- 2015-10-21 HU HUE15794641A patent/HUE050318T2/hu unknown
- 2015-10-21 DK DK20177260.5T patent/DK3783027T3/da active
- 2015-10-21 EP EP20177260.5A patent/EP3783027B1/en active Active
- 2015-10-21 ES ES15794641T patent/ES2817074T3/es active Active
-
2021
- 2021-06-21 JP JP2021102148A patent/JP7253008B2/ja active Active
-
2022
- 2022-05-20 US US17/749,856 patent/US20220281993A1/en not_active Abandoned
-
2023
- 2023-03-24 JP JP2023047480A patent/JP2023078398A/ja active Pending
-
2024
- 2024-04-25 US US18/645,607 patent/US20240294659A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538669A5 (2) | ||
| Chen et al. | Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response | |
| Gottstein et al. | Susceptibility versus resistance in alveolar echinococcosis (larval infection with Echinococcus multilocularis) | |
| Khammari et al. | Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones | |
| MX2019005125A (es) | Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular. | |
| EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
| JP2009525478A5 (2) | ||
| Conti et al. | Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB‐neuT Mice | |
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| MX2023001945A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
| JP2016501013A5 (2) | ||
| WO2007071389A1 (en) | Method for treating disseminated cancer | |
| EA201591219A1 (ru) | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение | |
| WO2019079624A3 (en) | Msi from liquid biopsies | |
| Costa et al. | Diagnosis of human strongyloidiasis: Application in clinical practice | |
| WO2021150936A1 (en) | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer | |
| WO2020081579A8 (en) | Monoclonal antibodies against human dickkopf3 and uses thereof | |
| Woller et al. | Virus infection, inflammation and prevention of cancer | |
| Goto et al. | DSP-7888, a novel cocktail design of WT1 peptide vaccine, and its combinational immunotherapy with immune checkpoint-blocking antibody against PD-1 | |
| Cachot et al. | 545 Tumor-specific cytolytic CD4 T cells mediate protective immunity against human cancer | |
| CN116940378A (zh) | 神经内分泌癌的治疗 | |
| Jacobsen et al. | 544 Multiomic characterization of T-cell populations at the single-cell level utilizing sensitive dextramers and BD® AbSeq on the BD RhapsodyTM Single-Cell Analysis system | |
| Jin et al. | IMMU-15. A UNIQUE SELF-STIMULATIVE PROPERTY OF CD70 CAR ADVANCES T CELL FUNCTION AND ANTI-TUMOR RESPONSE IN GLIOBLASTOMA | |
| Vaishnav et al. | Nanobytes-molecular and immuno-oncology | |
| Laspidea et al. | IMMU-14. ONCOLYTIC VIRUS EXPRESSING A POSITIVE IMMUNE CHECKPOINT MODULATOR AS A THERAPEUTIC APPROACH FOR DIPG |